AWAK Technologies has obtained more than $20m in Series B funding for the US-based pivotal trial of its wearable dialysis device.

Co-led by Vickers Venture Partners and Lion X Ventures, the round included participation from investors Eckuity Capital and Advanced MedTech.

Called AWAK PD, the ultra-portable peritoneal dialysis (PD) system allows kidney disease patients to undergo dialysis at home and anywhere on the go.

The company will use the proceeds for various crucial initiatives to conclude its ongoing human pre-pivotal clinical study with Singapore General Hospital.

The funding will also help the company improve the ultraportable PD device for the final pivotal trial in the US, anticipated to begin in 2025.

It will further enable the advanced development of new products, including complementary products to support home dialysis and integrate digital solutions for enhancing the home-based care of chronic kidney disease patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AWAK Technologies CEO Suresha Venkataraya said: “The significant investment in this round, at a higher valuation than our Series A, is a testament to the remarkable progress we’ve made with our ultraportable device and strategic portfolio expansion.

“This investment now propels us towards new and exciting milestones, including further development of our PD product and an upcoming pivotal clinical trial in the US.”